Ivabradine Zentiva

Ivabradine, the active ingredient in Ivabradine Zentiva, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for the management of chronic heart failure (NYHA class II–III) and stable angina pectoris, helping to reduce heart rate without compromising myocardial contractility.

GNH USA supplies Ivabradine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets worldwide while adhering to stringent quality and regulatory standards.

Ivabradine is an If channel inhibitor used in cardiovascular conditions to control heart rate.

Chronic heart failure (NYHA class II–III): Improves symptoms and reduces hospitalization risk by lowering heart rate. Stable angina pectoris: Decreases frequency of angina attacks through heart‑rate reduction. Elevated resting heart rate where beta‑blockers are unsuitable: Provides rate control without affecting myocardial contractility.

Common Side Effects: - Bradycardia: heart rate falls below the desired range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or fatigue: especially during initial therapy.

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Hepatic enzyme elevation indicating possible liver involvement.

Before starting therapy, evaluate patient suitability and monitor parameters regularly.

Assess heart rate before initiation: ensure resting HR ≥ 60 bpm. Monitor for symptomatic bradycardia: discontinue if HR < 50 bpm or patient experiences dizziness. Avoid use in patients with severe hepatic impairment. Caution in patients with hypotension or concurrent rate‑lowering agents. Pregnancy and lactation: safety not established; weigh risks and benefits. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ivabradine may interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure. - Co‑administration with other bradycardic agents (e.g., beta‑blockers, digoxin) can cause excessive heart‑rate reduction. - Use with verapamil or diltiazem (CYP3A4 inhibitors) increases risk of bradycardia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine) may reduce efficacy. - Drugs that prolong QT interval may increase arrhythmia risk.